155 related articles for article (PubMed ID: 22651685)
1. Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.
Zhang Q; Liu X; Xu S; Li C; Zhang Y; Yang J; Zheng J
Cancer Biother Radiopharm; 2012 Aug; 27(6):384-91. PubMed ID: 22651685
[TBL] [Abstract][Full Text] [Related]
2. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma.
Zhang Q; Liu X; Li C; Liao D; Ouyang Z; Zheng J; Song X
Oncol Lett; 2013 Sep; 6(3):801-806. PubMed ID: 24137414
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
[TBL] [Abstract][Full Text] [Related]
5. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
[TBL] [Abstract][Full Text] [Related]
8. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
[TBL] [Abstract][Full Text] [Related]
9. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
10. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.
Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS
PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246
[TBL] [Abstract][Full Text] [Related]
11. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
12. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
[TBL] [Abstract][Full Text] [Related]
13. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
[TBL] [Abstract][Full Text] [Related]
14. Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation.
Liu WJ; Liu XJ; Li L; Li Y; Zhang SH; Zhen YS
Cancer Immunol Immunother; 2014 Dec; 63(12):1261-72. PubMed ID: 25164878
[TBL] [Abstract][Full Text] [Related]
15. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
Cao HY; Guo XF; Zhu XF; Li SS; Zhen YS
Oncol Rep; 2017 Jun; 37(6):3329-3340. PubMed ID: 28498434
[TBL] [Abstract][Full Text] [Related]
16. A Gelatinases-targeting scFv-based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma.
Gao R; Li L; Shang B; Zhao C; Sheng W; Li D
Basic Clin Pharmacol Toxicol; 2015 Aug; 117(2):105-16. PubMed ID: 25615234
[TBL] [Abstract][Full Text] [Related]
17. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
18. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
19. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice.
Zhong G; Zhang S; Li Y; Liu X; Gao R; Miao Q; Zhen Y
Cancer Lett; 2010 Sep; 295(1):124-33. PubMed ID: 20303650
[TBL] [Abstract][Full Text] [Related]
20. [Construction of energized fusion protein consisting of epidermal growth factor receptor oligopeptide ligand and lidamycin and its antitumor activity].
Guo XF; Zhong GS; Miao QF; Zhen YS
Ai Zheng; 2009 Jun; 28(6):561-8. PubMed ID: 19635191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]